Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BY-NC-NDTranslational lung cancer research

Amivantamab and lazertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with brain and leptomeningeal metastases: an editorial on efficacy, challenges in assessment, and future directions.

  • Vinay R Nittur1
  • Yoojin Jo2
  • Misako Nagasaka1,3
  1. 1Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Orange, CA, USA.
  2. 2College of Arts & Sciences, University of Pennsylvania, Philadelphia, PA, USA.
  3. 3Division of Neurology, Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Read full textPDFDOICite

Related

  1. Beyond the blood-brain barrier: amivantamab plus lazertinib in EGFR-mutant non-small cell lung cancer with brain and leptomeningeal metastases.
    Kelsey Pan, Shi-Yong Sun
    Translational lung cancer researchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  2. Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
    Hidetoshi Hayashi, Byoung Chul Cho, David R. Spigel +19
    Journal of Thoracic OncologyPeer-reviewedCC BY5 citedOncologyHAL
  3. First-Line Lorlatinib for ALK-Rearranged Pulmonary Large-Cell Neuroendocrine Carcinoma with Brain Metastases and Suspected Leptomeningeal Involvement: A Case Report and Literature Review
    Yoshio Nakano, Kazuya Nishimura, Hiroka Serizawa +5
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  4. Case Report: Prolonged survival following multimodal treatment of leptomeningeal metastases in triple-negative glycogen-rich clear cell breast carcinoma
    Yun-Chih Lo, Chun-Chieh Wu, Shang-Chun Hung +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  5. Commentary: Assessment of real-world surveillance strategies for patients undergoing systemic therapy for brain metastases
    Xiaoxia Zhang, Guanjie Wang, Xiaoling Guo +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref

Cite

BibTeXRIS
BibTeX
@article{nittur2026amivantamab,
  title = {{Amivantamab and lazertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with brain and leptomeningeal metastases: an editorial on efficacy, challenges in assessment, and future directions.}},
  author = {Vinay R Nittur and Yoojin Jo and Misako Nagasaka},
  journal = {Translational lung cancer research},
  year = {2026},
  month = oct,
  doi = {10.21037/tlcr-2026-1035},
  url = {https://europepmc.org/article/MED/42999606},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Amivantamab and lazertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with brain and leptomeningeal metastases: an editorial on efficacy, challenges in assessment, and future directions.
AU  - Vinay R Nittur
AU  - Yoojin Jo
AU  - Misako Nagasaka
PY  - 2026
DA  - 2026/10/26
JO  - Translational lung cancer research
DO  - 10.21037/tlcr-2026-1035
UR  - https://europepmc.org/article/MED/42999606
SN  - 2218-6751
SN  - 2226-4477
ER  -